AI developer Anthropic has acquired New York-based biotech startup Coefficient Bio for about $400 million, according to The Information.
Coefficient Bio, which was founded last fall and operates primarily in stealth, will be absorbed directly into Anthropic’s Healthcare Life Sciences division.
Despite having fewer than 10 employees, the startup has garnered huge valuations for its specialized platform that leverages AI to map drug research and development, identify novel drug targets, and manage clinical regulatory strategy.
This acquisition serves as a highly profitable acquisition that secures top talent working at the increasingly competitive intersection of machine learning and biology.
Coefficient’s founding team includes CEO Aris Theologis, a veteran of Evozyne and Paragon Biosciences, as well as CTO Nathan Frey and co-founder Samuel Stanton, both of whom previously worked in machine learning at Roche’s Genentech.
Since aggressively growing its corporate development team last year, Anthropic has been actively pursuing data licensing agreements and strategic acquisitions to further deepen its vertical market penetration.
The integration of the Coefficient Bio team, which reports directly to Eric Kauderer-Abrams, head of Anthropic Healthcare, strengthens a division that already serves major pharmaceutical companies including Sanofi (NASDAQ:SNY), Novo Nordisk (NYSE:NVO), AbbVie (NYSE:ABBV) and Genmab (NASDAQ:GMAB).
Anthropic has been steadily laying the foundation for this expansion. Last October, the company launched Claude Life Sciences, upgrading its flagship model to integrate with industry-standard scientific tools such as Benchling and BioRender.
By January, Anthropic expanded into a HIPAA-compliant healthcare environment and introduced specialized capabilities that allow it to draft clinical trial protocols and prepare them for regulatory submissions.
Amid acquisitions, major pharmaceutical companies are also now scrambling to secure access to advanced algorithms as part of the critical infrastructure for next-generation therapeutics.
Just last week, Eli Lilly & Company (NYSE:LLY) committed up to $2.75 billion to expand its AI-powered drug design partnership with Insilico Medicine.
Days earlier, Earendil Labs secured $787 million in a private placement backed by Sanofi and Pfizer (NYSE:PFE) to fund its AI-generated drug pipeline, which currently boasts more than 40 programs.
don’t forget to follow @INN_Life Science Get real-time updates!
Securities Disclosure: I, Giann Liguid, have no direct investment interest in any companies mentioned in this article.
